| abstract |
Provided is an anti-HIV polypeptide modified with polyethylene glycol (PEG). Specifically, cysteine is added to the N-terminus, C-terminus, or position 10 of a C34 polypeptide, and the C34 polypeptide is subjected to a Michael addition reaction to couple a maleimide-modified PEG group to said cysteine, so as to modify the C34 polypeptide via PEGylation, wherein the molecular weight of the PEG moiety is 10000 or higher, preferably from 10000 to 100000, and more preferably from 10000 to 50000. The modified C34 polypeptide has an obvious increase in water solubility and serum half-life in rats, can enter lymph nodes more easily, and has a stronger antiviral activity against HIV in rhesus monkeys acutely infected with SHIV SF162P3. Also provided are a preparation method for the anti-HIV polypeptide modified with PEG, and a use of the anti-HIV polypeptide modified with PEG. |